Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
LI2-C52H3 | Cynomolgus | Cynomolgus LILRB2 / CD85d / ILT4 Protein, His Tag | ![]() |
![]() ![]() |
|
LI2-C82E3 | Cynomolgus | Biotinylated Cynomolgus LILRB2 / CD85d / ILT4 Protein, His,Avitag™ | ![]() |
![]() ![]() |
|
LI2-H82F5 | Human | Biotinylated Human LILRB2 / CD85d / ILT4 Protein, Fc,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
|
CDD-H5259 | Human | Human LILRB2 / CD85d / ILT4 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
LI2-H5220 | Human | Human LILRB2 / CD85d / ILT4 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Human LILRB2, His Tag (Cat. No. LI2-H5220) at 1 μg/mL (100 μL/well) can bind Anti-LILRB2 Antibody, Human IgG1 with a linear range of 0.5-4 ng/mL (QC tested).
The purity of Biotinylated Human LILRB2, Fc,Avitag (Cat. No. LI2-H82F5) is more than 90% and the molecular weight of this protein is around 165-201 kDa verified by SEC-MALS.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
NGM-707 | NGM-707 | Merck & Co, Ngm Biopharmaceuticals | Details | ||
IO-108 | IO-108 | Phase 1 Clinical | Immune-Onc Therapeutics Inc | Solid tumours | Details |
JTX-8064 | JTX-8064 | Jounce Therapeutics | Details | ||
MK-4830 | MK-4830 | Phase 2 Clinical | Merck Sharp & Dohme Corp | Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; uterine serous carcinoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.